A pharmaceutical partner hands over a molecule and receives better material. In between sits our autonomous crystallisation module, flown on third-party commercial spacecraft.
Our module operates aboard a commercial spacecraft with re-entry capability. The cycle runs end to end without astronauts, space stations, or partner involvement.
The ZGW module, loaded with the partner's molecule, is integrated into a third-party commercial spacecraft.
The spacecraft flies on a rideshare launch — routine, scheduled, and no longer the hard part.
The spacecraft is placed in orbit at roughly 500 km, in sustained microgravity.
The module crystallises the drug substance autonomously, under diffusion-limited conditions gravity makes impossible on Earth.
The spacecraft re-enters the atmosphere and is recovered, with the material sealed and protected.
The crystallised drug substance is delivered to the partner's facility — kilogram-scale material under agreed quality and documentation standards.
One crystallisation core, three build stages — each de-risking the next. Between the lab bench and orbit, only gravity changes.
A lab-bench instrument with the same crystallisation core as the flight unit. It runs the process at 1g, produces the baseline data, and trains the module's autonomous control.
A small autonomous satellite that crystallises the drug substance in orbit and sends the data back — proving the process in microgravity before any material needs to come home.
The recovery-class module: it crystallises the partner's molecule in orbit inside a cargo-return capsule and brings kilogram-scale drug substance back to Earth.